| Literature DB >> 31540101 |
Michaela Šadibolová1, Tomáš Zárybnický2, Tomáš Smutný3, Petr Pávek4, Zdeněk Šubrt5,6, Petra Matoušková7, Lenka Skálová8, Iva Boušová9.
Abstract
Sesquiterpenes, the main components of plant essential oils, are bioactive compounds with numerous health-beneficial activities. Sesquiterpenes can interact with concomitantly administered drugs due to the modulation of drug-metabolizing enzymes (DMEs). The aim of this study was to evaluate the modulatory effects of six sesquiterpenes (farnesol, cis-nerolidol, trans-nerolidol, α-humulene, β-caryophyllene, and caryophyllene oxide) on the expression of four phase I DMEs (cytochrome P450 3A4 and 2C, carbonyl reductase 1, and aldo-keto reductase 1C) at both the mRNA and protein levels. For this purpose, human precision-cut liver slices (PCLS) prepared from 10 patients and transfected HepG2 cells were used. Western blotting, quantitative real-time PCR and reporter gene assays were employed in the analyses. In the reporter gene assays, all sesquiterpenes significantly induced cytochrome P450 3A4 expression via pregnane X receptor interaction. However in PCLS, their effects on the expression of all the tested DMEs at the mRNA and protein levels were mild or none. High inter-individual variabilities in the basal levels as well as in modulatory efficacy of the tested sesquiterpenes were observed, indicating a high probability of marked differences in the effects of these compounds among the general population. Nevertheless, it seems unlikely that the studied sesquiterpenes would remarkably influence the bioavailability and efficacy of concomitantly administered drugs.Entities:
Keywords: cytochrome P450 3A4; gene reporter assay; mRNA expression; precision-cut liver slices; pregnane X receptor; protein expression; sesquiterpene
Mesh:
Substances:
Year: 2019 PMID: 31540101 PMCID: PMC6769599 DOI: 10.3390/ijms20184562
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Chemical structures of the studied sesquiterpenes.
Figure 2The effect of sesquiterpenes on the AhR and PXR receptors. HepG2 cells were transiently transfected with either p1A1-luc (A) or p3A4-luc in combination with expression vectors pSG5-PXR and pSG5-RXRα (B). The next day, the cells were treated with the tested compounds for 24 h. AhR and PXR as well as the well-known ligands methylcholanthrene (MC, 10 μM) and rifampicin (RIF, 10 μM) were used as positive controls. The samples were subsequently assayed by a Dual-Luciferase Reporter Assay System (Promega). The results are presented as the relative change to DMSO-treated controls defined as 100% (n = 3). * p < 0.05.
Figure 3Inter-individual variability in the basal expression of selected mRNAs (A) and proteins (B) in PCLS from ten patients. The horizontal line represents the median, and whiskers represent the maximum and minimum values.
Figure 4Inter-individual differences in the effect of linear sesquiterpenes (10 μM) and RIF (10 μM) on the normalized mRNA expression of CYP3A4 (A), CYP2C (B), CBR1 (C) and AKR1C (D) in human PCLS from five patients after 24 h (n = 3). The normalized expression level was calculated using the 2−ΔΔCt method with the geometric mean of GAPDH and SDHA as a reference gene. Results are presented as the mean ± SD (n = 3). Statistical analyses were performed using one-way ANOVA with Dunnett’s test: p < 0.05 (*).
Figure 5Inter-individual differences in the effect of sesquiterpenes (10 μM) and RIF (10 μM) on the normalized protein expression of CYP3A4 (A,B) and CBR1 (C,D) in human PCLS from ten patients after 24 h (n = 3). The protein expression was calculated using calnexin as a loading control. Results are presented as the mean ± SD (n = 4), with controls set to 100%. Statistical analyses were performed using one-way ANOVA with Dunnett’s test: p < 0.05 (*).
Brief medical history of liver tissue donors.
| Liver Sample | Sex (Age) | Reason of Surgery | Comorbidities | Long-Term Pharmacotherapy |
|---|---|---|---|---|
|
| male (63) | Colorectal carcinoma | HTN, hyperuricemia, type 2 DM | Ramipril, atorvastatin, metformin, allopurinol |
|
| male (69) | Colorectal carcinoma | HTN | Hydrochlorothiazide |
|
| male (69) | Colorectal carcinoma | HTN, s/ | Acetylsalicylic acid, nitrendipine |
|
| male (81) | Colorectal carcinoma | HTN, dyslipidemia | Betaxolol |
|
| female (57) | Colorectal carcinoma | none | none |
|
| female (45) | Benign focal nodular hyperplasia | none | none |
|
| female (59) | Colorectal carcinoma | HLD, ovarian cancer | none |
|
| female (65) | Colorectal carcinoma | HTN, HLD, impaired glucose tolerance | Amlodipine |
|
| female (78) | Cholangiocellular carcinoma | HTN, HLD, coronary artery disease, atrial fibrillation | Bisoprolol, furosemide, ramipril, simvastatin, enoxaparin, zolpidem |
|
| male (59) | Cholangiocellular carcinoma | none | none |
HTN, arterial hypertension; DM, diabetes mellitus; s/p CVA, status post cerebrovascular accident; HLD, hyperlipidemia.
List of primers used for RT-qPCR analysis of the selected genes.
| Gene | Forward Primer | Reverse Primer |
|---|---|---|
| CYP3A4 | CCCCTGAAATTAAGCTTAGGAGG | CTGGTGTTCTCAGGCACAGA |
| CYP2C | TTTGGGATGGGGAAGAGGAG | GGAGCACAGCCCAGGAT |
| CBR1 | TTGGTACCCGAGATGTGTGC | CTTGGGGTTTTATTAGAGGGAG |
| AKR1C | ATGAGGAGCAGGTTGGACTG | GCTTTGAAGTGTAGAATATGTCTTCT |